Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

Rocketman808 Aug. 17 at 11:08 PM

$FATE gut feeling. big action tomorrow

0 · Reply

Tacto Aug. 17 at 11:25 AM

$FATE The picture shows stockholders with more than a million shares. Redmile reported on July 3rd that they added over 5M shares, making for a current total of just about 18M shares https://whalewisdom.com/stock/fate

0 · Reply

radonco Aug. 16 at 11:03 PM

$FATE some hedge funds decreased a lot like Goldman and schonfeld…baker bros reduced 23%, redmile and blackrock still holding…vanguard reduced 15%…strange at these lower prices…would have thought a run up to $3-5 for tutes to dump shares…I’m holding long term but surprised at filings

1 · Reply

giuseppe8469 Aug. 15 at 11:55 PM

$FATE wait to biotech rips Monday !!!

1 · Reply

DNAedit Aug. 15 at 6:29 PM

$FATE probably buy more next week sub $1.

0 · Reply

vu_jade Aug. 15 at 4:58 PM

$FATE no worries

0 · Reply

Jake140 Aug. 15 at 10:51 AM

$FATE

0 · Reply

None_ Aug. 15 at 1:43 AM

$FATE https://www.globenewswire.com/en/news-release/2025/08/12/3132097/24675/en/fate-therapeutics-reports-second-quarter-2025-financial-results-and-business-updates.html

0 · Reply

BEATOFtheMARKET Aug. 14 at 3:50 PM

$FATE signal 54.5%

0 · Reply

giuseppe8469 Aug. 13 at 8:43 PM

$FATE nothing worse the. Bears spouting nonsense with no thesis to there words no use for them at all

0 · Reply

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 4:01 PM EDT - 12 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2025, 9:00 AM EDT - 2 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 2 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 2 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 3 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 6:22 PM EDT - 3 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Apr 29, 2025, 9:25 AM EDT - 3 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 4 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 5, 2025, 4:01 PM EST - 5 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 4, 2025, 4:01 PM EST - 5 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Feb 14, 2025, 4:01 PM EST - 6 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2025, 7:41 PM EST - 6 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Dec 9, 2024, 4:01 PM EST - 8 months ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 9 months ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 9 months ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 20, 2024, 4:34 PM EST - 9 months ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 18, 2024, 8:05 AM EST - 9 months ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 9 months ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 10 months ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 10 months ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 1 year ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2023, 12:10 PM EST - 1 year ago

Fate Therapeutics: Getting There, But Perpetually

Nov 8, 2023, 9:12 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

May 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 23, 2023, 1:40 PM EDT - 2 years ago

Fate Therapeutics: The Future Remains Cloudy

Rocketman808 Aug. 17 at 11:08 PM

$FATE gut feeling. big action tomorrow

0 · Reply

Tacto Aug. 17 at 11:25 AM

0 · Reply

radonco Aug. 16 at 11:03 PM

1 · Reply

giuseppe8469 Aug. 15 at 11:55 PM

$FATE wait to biotech rips Monday !!!

1 · Reply

DNAedit Aug. 15 at 6:29 PM

$FATE probably buy more next week sub $1.

0 · Reply

vu_jade Aug. 15 at 4:58 PM

$FATE no worries

0 · Reply

Jake140 Aug. 15 at 10:51 AM

$FATE

0 · Reply

None_ Aug. 15 at 1:43 AM

$FATE https://www.globenewswire.com/en/news-release/2025/08/12/3132097/24675/en/fate-therapeutics-reports-second-quarter-2025-financial-results-and-business-updates.html

0 · Reply

BEATOFtheMARKET Aug. 14 at 3:50 PM

$FATE signal 54.5%

0 · Reply

giuseppe8469 Aug. 13 at 8:43 PM

$FATE nothing worse the. Bears spouting nonsense with no thesis to there words no use for them at all

0 · Reply

IBOTTheDipAndTheDipWon Aug. 13 at 5:59 PM

$FATE Damn, this is like watching lead-based paint dry.

0 · Reply

Cankles_McTaco_Tits Aug. 13 at 5:16 PM

$FATE missed the $1.26... back there again soon

0 · Reply

tltisbae Aug. 13 at 4:17 PM

$FATE sold today after buying yesterday lol

0 · Reply

IBOTTheDipAndTheDipWon Aug. 13 at 3:56 PM

$FATE Look on the bright side, at least this company won't have to worry about income taxes!

0 · Reply

IBOTTheDipAndTheDipWon Aug. 13 at 3:53 PM

$FATE Push for 1.32 bulls!

0 · Reply

dbr_island Aug. 13 at 3:50 PM

$BSLK just broke $8 💰💰💰 $9 is next CELZ is my next one loading 🚢📦📦📦📦📦🚨 $FATE $GV $MNTS $WBTN what a day

0 · Reply

IBOTTheDipAndTheDipWon Aug. 13 at 3:44 PM

$FATE When this moves to OTC maybe they can rename it FATAL?

1 · Reply

Southshd Aug. 13 at 3:20 PM

$FATE nice move today 200k shares long and strong!! Allo will follow tomorrow they always do…. 180k shares to be transparent

1 · Reply

giuseppe8469 Aug. 13 at 2:20 PM

$FATE that was an mm shakeout at its best !! There is no one short this stock believe me

1 · Reply

S_Franconi Aug. 13 at 2:08 PM

$FATE Thanks $FATE!

0 · Reply

Rocketman808 Aug. 13 at 2:04 PM

$FATE kidding, give me a fckn buyout tomorrow. 11.50. we all deserve it

0 · Reply

Rocketman808 Aug. 13 at 2:03 PM

$FATE fyi XBI breaking out too which may help this sustain. wouldnt mind a multi day pump and settle around 1.50 for now

0 · Reply

Market Cap	125.71M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,366.54%
Debt to Equity Ratio	0.00

Volume	1,679,800
Avg Vol	1,745,180
Day's Range	N/A - N/A
Shares Out	115.33M
Stochastic %K	55%
Beta	2.24
Analysts	Sell
Price Target	$5.47